Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Prepaid Assets (2022 - 2025)

Historic Prepaid Assets for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $14.6 million.

  • Day One Biopharmaceuticals' Prepaid Assets rose 3085.04% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 3085.04%. This contributed to the annual value of $13.4 million for FY2024, which is 5025.2% up from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Prepaid Assets stood at $14.6 million, which was up 3085.04% from $15.1 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Prepaid Assets high stood at $402.5 million for Q2 2022, and its period low was $5.6 million during Q4 2022.
  • Moreover, its 4-year median value for Prepaid Assets was $13.4 million (2024), whereas its average is $99.4 million.
  • In the last 5 years, Day One Biopharmaceuticals' Prepaid Assets tumbled by 9828.52% in 2023 and then soared by 7393.51% in 2024.
  • Over the past 4 years, Day One Biopharmaceuticals' Prepaid Assets (Quarter) stood at $5.6 million in 2022, then surged by 59.27% to $8.9 million in 2023, then surged by 50.25% to $13.4 million in 2024, then rose by 9.1% to $14.6 million in 2025.
  • Its last three reported values are $14.6 million in Q3 2025, $15.1 million for Q2 2025, and $14.0 million during Q1 2025.